MOTS-c Dosage: Frequency, Cycling and Stacking with NAD+

What's the MOTS-c dosage?

A typical MOTS-c dosage is 2.5 to 5 mg, three times weekly. It goes in subcutaneously, meaning under the skin. That's the starting range. Most people step it up over four to six weeks to a maintenance range of 5 to 10 mg, three to five times weekly.

Those figures don't come from a finished human dosing trial. They come from anecdotal reports across the research and biohacking community. So treat them as a starting reference, not a fixed prescription.

Why inject at all? Oral MOTS-c is broken down by gut enzymes before it ever reaches your blood. No oral form on the market or in development gets past that. Subcutaneous injection is the only clinically relevant route. You inject typically into the abdomen or thigh.

MOTS-c dosage chart

Here's the MOTS-c peptide dosage chart. Every row is built from figures already on this page. Nothing in it is invented to fill a gap.

The last row isn't native MOTS-c. CB4211 is a MOTS-c analog, meaning a close copy of the molecule. It's in the chart because it's the only human dose we have.

MOTS-c dosage per day: how much?

Most protocols aren't daily at all. They run three to five injections a week.

One daily figure does exist in human research. The CB4211 trial dosed 25 mg per day subcutaneously for four weeks, in obese patients with fatty liver disease. That was the analog, not native MOTS-c. So it isn't a daily dose for the peptide itself.

MOTS-c dosage per week: how much?

Three to five shots under the skin per week is the common pattern. A single large weekly dose isn't.

The reason is the peptide's half-life, which is short. Half-life just means how fast your body clears it. The signal looks steadier with repeated, closely spaced doses. One big weekly shot doesn't hold it.

What's the full MOTS-c dosage protocol?

Start low, hold, then step up. The MOTS-c dosage protocol most people follow runs 2.5 mg three times weekly for two weeks.

Where do these figures come from? They're extrapolated from that CB4211 trial, from rodent metabolic studies using weight-based dosing, and from user-reported anecdotal experience. No completed Phase 2 or 3 trial has established an optimal human dose for native MOTS-c.

Then it moves to 5 mg three times weekly for two to four weeks. After that, some go to 5 to 10 mg, three to five times weekly. Only make that move if metabolic markers and tolerance support it.

The first one to two weeks exist to assess your own tolerance. That's their whole job. Always work with a qualified clinician before making changes to your health protocol, particularly one involving an unregulated, non-FDA-approved peptide.

When's the best time to inject MOTS-c?

The most common timing reported is a morning shot, 30 to 60 minutes ahead of a training session.

The logic is simple. MOTS-c and exercise both converge on AMPK, the energy-sensing switch your body flips during training. Stack the two close together and you may compound the metabolic signal.

If your blood sugar swings, watch a fasted shot closely. Don't assume it feels the same as a fed-state one.

Is there a MOTS-c dosage for weight loss?

No. There's no published MOTS-c dosage for weight loss, and I'm not going to invent one for you.

Here's what the evidence does cover. In animal models, MOTS-c prevented diet-induced obesity, which I unpack under how it works below. The CB4211 trial ran in obese patients with fatty liver disease. It measured liver enzymes and blood glucose.

So the direction of travel is interesting. A dose aimed at fat loss isn't there yet.

How long should a MOTS-c cycle run?

There's no published human evidence defining an optimal MOTS-c cycle length. Common practice runs four to twelve week cycles, followed by a washout period.

That comes from general peptide-cycling logic. It isn't data specific to MOTS-c desensitization or receptor downregulation.

Why cycle at all? It's a precaution. AMPK is a powerful signaling pathway. Flip any metabolic switch on non-stop and you risk a blunted response over time. That risk is theoretical, and it's the same concern that drives cycling logic in other AMPK-adjacent compounds.

Nobody has studied this directly for MOTS-c in humans. So play it safe. Run a defined cycle. Take a break of similar or longer length. Recheck your biomarkers before you start again, rather than running daily and never stopping.

MOTS-c peptide human dosage: what the evidence shows

It's thin. There's one completed human trial, and it used CB4211, a MOTS-c analog, not native MOTS-c.

Phase 1a was a safety study in 65 healthy adults. Phase 1b was an efficacy study in 20 obese patients with fatty liver disease, dosed at 25 mg per day subcutaneously for four weeks.

Phase 1b reported meaningful reductions in liver enzymes. ALT fell roughly 21 percent and AST roughly 28 percent. Blood glucose also dropped relative to placebo. No serious adverse events were reported across either study arm.

That's a genuinely encouraging early signal. It's still an analog molecule in a small, short trial. It doesn't validate the native MOTS-c dosing protocols people run.

Preclinical work goes further, into heart tissue repair. In a rodent (rat) model of diabetic heart dysfunction, daily MOTS-c injection restored mitochondrial bioenergetic function and contractile performance over three weeks (Pham 2025).

Separate work in cells and in live animals showed MOTS-c helps repair damaged cell membranes. That happens during ischemia and reperfusion stress, meaning blood flow cut off and then restored. It works by interacting with the membrane-repair protein TRIM72 (Jia 2024).

Both are preclinical, animal-model findings, not human trial evidence. Read them as support for the biology, not proof of human benefit.

Is MOTS-c safe, and is it banned?

MOTS-c has no FDA approval and no completed Phase 2 or later human trial. It's also banned by WADA under the 2024 Prohibited List, as an AMPK activator.

No therapeutic use exemption is available. So if you compete under WADA rules, MOTS-c is off the table entirely.

Side effects in the CB4211 trial were mild. They were localized injection site reactions: redness, itching and discomfort. There were no serious adverse events across either study phase.

Anecdotal reports in the broader biohacking community mention heart palpitations and elevated heart rate with native MOTS-c. Those are unverified user reports, not data from a published safety study. Weigh them that way.

The bigger unknown is long-term human safety. There's no chronic-use human data for native MOTS-c. There's no established safe upper dosing threshold either.

And there's no data on what sustained AMPK activation does to endocrine or immune markers over months or years.

If you decide to research this compound, get baseline bloodwork first. Fasting glucose, HbA1c, insulin, a lipid panel and liver enzymes give you something concrete to track. That beats going in blind. Always work with a qualified clinician before making changes to your health protocol.

Can you stack MOTS-c with NAD+?

Yes. It's a common pattern in metabolic health research protocols. The two target complementary parts of the same mitochondrial system.

MOTS-c switches on AMPK, which turns up metabolic and stress-adaptation gene expression. NAD+ supplies the substrate that sirtuins need. Sirtuins are repair enzymes. They drive mitochondrial biogenesis, meaning your cells build new mitochondria, and cellular repair.

Recent preclinical work adds a direct link. In aged pancreatic islet cells, MOTS-c treatment increased NAD+ levels and reduced markers of cellular senescence. Glucose tolerance also improved in aged rodent (mouse) models (MOTS-c and pancreatic beta-cell senescence, 2025).

So the pairing isn't just theory. The two may interact at the cellular level, especially around age-related metabolic decline.

In practice, most people run MOTS-c under the skin on the schedule above. They layer NAD+ in by their preferred route, whether that's a shot under the skin, IV, or an oral precursor like NMN or NR.

No published human trial has tested the two together. So the case rests on mechanistic plausibility, not confirmed synergy.

What is MOTS-c and how does it work?

MOTS-c is a 16-amino-acid peptide. Your mitochondrial DNA encodes it, not your nuclear genome. Researchers first identified it in 2015. They have studied it since as an exercise-mimetic metabolic regulator, meaning it copies part of what training does.

It switches on AMPK, the same energy-sensing switch your body flips during training. That's why researchers frame it as a way to trigger exercise-like metabolic signaling pharmacologically, meaning by injection rather than by training.

The name stands for mitochondrial open reading frame of the 12S rRNA-c. It's one of a small family of mitochondrial-derived peptides your cells make naturally.

It acts less like a hormone and more like a messenger. It travels from your mitochondria back to your cell nucleus. There it switches on stress-adaptation genes.

The foundational work showed MOTS-c regulates insulin sensitivity. It also prevents diet-induced obesity in animal models, by switching on AMPK, the same pathway exercise engages (Lee 2016).

The peptide is conserved across at least 14 species. That tells you the pathway it controls is ancient and fundamental, not a fluke.

In human tissue, MOTS-c expression rises in skeletal muscle and blood after exercise. Levels are documented to fall with age and with metabolic disease. That fall correlates with reduced insulin sensitivity and lower exercise capacity (Zheng 2023).

That age-related decline is the core argument for supplementing it. If your own MOTS-c drops off as you get older, restoring it might restore some of the metabolic flexibility that goes with it.

MOTS-c drives its effects through the Folate-AICAR-AMPK pathway. AICAR is a molecule that builds up and directly switches on AMPK. AMPK then reaches into the nucleus. There it changes how hundreds of stress-response and metabolic genes are expressed (Wan 2023).

Downstream of that, MOTS-c improves glucose uptake in skeletal muscle. It does that by moving GLUT4 transporters to the cell surface. That's the same mechanism that makes a hard training session improve your insulin sensitivity for the following 24 to 48 hours.

What should you check before buying MOTS-c?

Third-party purity and identity testing. That's the single most important check you can run before using any batch.

MOTS-c sits entirely outside FDA oversight. So product quality varies enormously between suppliers. A certificate of analysis from an independent lab is the baseline, not a nice-to-have.

Peptides sold outside a licensed compounding pharmacy carry no regulatory guarantee. Not of purity, not of concentration, not even of correct identity.

If you're researching where to source MOTS-c, see our recommended sources page. It's a vendor-neutral overview of what third-party testing and documentation to look for. If you're researching this compound, I've linked a trusted source below. It supports the channel.

Our guide on how to know if peptides are real walks through the red flags to check before you buy. It covers how to read a certificate of analysis properly. And our tesamorelin dosage protocol breakdown covers a related, better-studied dosing framework.

References

Lee C, et al. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. PubMed.

Wan T, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. PMC.

Zheng D, et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. PMC.

Pham T, et al. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. PMC.

Jia D, et al. Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72. PMC.

Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes, Experimental & Molecular Medicine, 2025. Nature.

CohBar Announces Positive Topline Results from Phase 1a/1b Study of CB4211. GlobeNewswire.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.